Clarametyx Biosciences

We support the World Health Organization efforts to highlight the daunting challenge of antibiotic resistance during #WorldAMRAwarenessWeek. A wide range of global efforts are underway to address this threat through collaborative research and innovation.?#antibioticresistance

We’re honored to be named the?“Infectious Disease Innovation of the Year”?as part of the 2024 BioTech Breakthrough Awards! This is rewarding recognition for the momentum we are generating with our anti-biofilm antibody approach targeting chronic respiratory disease. See today’s announcement here. https://lnkd.in/e-TTWB6G

Patient access to life saving drugs to is a policy priority for Ohio Life Sciences. We were thrilled to host Congressman Michael T.W. Carey and State Representative Brian Lampton for a roundtable discussion with life sciences leaders Michael Triplett (Armatus Bio, Inc.), David V. Richards (Clarametyx Biosciences), Joe Bagan (STAQ Pharma), Willa Bluestone and Scott Howell to better understand the impact that policy has on drug manufacturing innovation and affordability. We appreciate Congressman Mike Carey’s focus on bi-partisan solutions to this complex federal and state policy issue!

CEO David V. Richards spoke with Contagion_Live as part of our data progress update at #IDWeek2024, explaining how our platform could enhance antibiotic effectiveness by targeting bacterial biofilms, a significant challenge in treatment.?Watch the full segment below.

Now published in Nature Portfolio! An excellent commentary on the challenge of the bacterial biofilm and the technology discovered by our scientific co-founders Drs. Lauren Bakaletz and Steve Goodman at Nationwide Children's Hospital along with collaborator Dr. John Hamilton at Rush University Medical Center. Read the full article here: https://lnkd.in/dp3tyUif

As part of our participation at #IDWeek2024, we are announcing a progress update on our trial of CMTX-101 for infections associated with cystic fibrosis (CF). Read today's release for more details. #infectiousdisease #innovation #biofilms https://lnkd.in/eKYvU-us

Better use of vaccines could reduce antibiotic use by 2.5 billion doses annually. #VaccinesWork to reduce the threat of #AntimicrobialResistance by:? ?? preventing an infection before it starts? ?? reducing the use and overuse of antibiotics? ?? slowing the emergence and spread of resistant pathogens? ? New WHO report finds vaccines could avert deaths, reduce antibiotic doses and save money from treating resistant infections: https://bit.ly/48k06KR??

David V. Richards, Steve St. Onge and Charles McOsker are heading out to LA this week for #IDWeek2024 to connect with colleagues, partners and collaborators on novel strategies to combat #infectiousdisease.?Join us for a discussion on antimicrobials in the pipeline on Friday, 8 am PT. See the full program here: https://lnkd.in/dHNhCf6 #infectiousdisease #AMR #antimicrobialresistance

Clarametyx has been selected to present as part of an antimicrobial pipeline session during IDWeek, which starts October 16th. We are eager to connect with experts across the global infectious disease community to discuss the challenge of bacterial #biofilms and our innovative approach to addressing antimicrobial resistance. Join us in Los Angeles! #IDWeek2024 #infectiousdisease #AMR #antimicrobialresistance https://lnkd.in/ebwyYDnQ

Today, the United Nations General Assembly is meeting on #antimicrobialresistance, a critical threat to global public health. As nations discuss global solutions, the #PASTEURAct is one of several important approaches that can help address the #superbug crisis. #AMR #UNGA2024